New vaccine aims to train immune system against hepatitis b
NCT ID NCT06989788
First seen Apr 24, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This early-stage study tests a new vaccine (AVX70371) designed to treat chronic hepatitis B. Researchers will give the vaccine to 16 healthy adults aged 18 to 40 to check its safety and how well it triggers an immune response. The goal is to see if the vaccine can help the body fight the hepatitis B virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC)
Ghent, Belgium
Conditions
Explore the condition pages connected to this study.